MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 10, 2008; DOI: 10.1124/mol.108.048520


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.048520v1
74/3/614    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Akk, G.
Right arrow Articles by Steinbach, J. H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akk, G.
Right arrow Articles by Steinbach, J. H.


Received for publication May 1, 2008.
Revised May 29, 2008.
Accepted for publication June 10, 2008.

Mutations of the GABA-A receptor {alpha}1 subunit M1 domain reveal unexpected complexity for modulation by neuroactive steroids

Gustav Akk 1*, Ping Li 1, John Bracamontes 1, David E Reichert 1, Douglas F Covey 1, Joseph H. Steinbach 1

1 Washington University School of Medicine

* Address correspondence to: E-mail: akk{at}morpheus.wustl.edu

Abstract

Neuroactive steroids are among the most efficacious modulators of the mammalian GABA-A receptor. Previous work has proposed that receptor potentiation is mediated by steroid interactions with a site defined by the residues {alpha}1N407/Y410 in the M4 transmembrane domain, and residue {alpha}1Q241 in the M1 domain. We examined the role of residues in the {alpha}1 subunit M1 domain in the modulation of the rat {alpha}1{beta}2{gamma}2L GABA-A receptor by neuroactive steroids. The data demonstrate that the region is critical to the actions of potentiating neuroactive steroids. Receptors containing the {alpha}1Q241W or {alpha}1Q241L mutations were insensitive to (3{alpha},5{alpha}-3-hydroxypregnan-20-one (3{alpha}5{alpha}P), albeit with different underlying mechanisms. The {alpha}1Q241S mutant was potentiated by 3{alpha}5{alpha}P but the kinetic mode of potentiation was altered by the mutation. Interestingly, the {alpha}1Q241L mutation was without effect on channel potentiation by (3{alpha},5{beta}-3-hydroxymethylpregnan-20-one, but mutation of the neighboring residue, {alpha}1S240, prevented channel modulation. A steroid lacking a H-bonding group on C3 (5{alpha}-pregnan-20-one) potentiated the wild-type receptor but not the {alpha}1Q241L mutant. The findings are consistent with a model where the {alpha}1S240 and {alpha}1Q241 residues shape the surface to which steroid molecules bind.


Key words: GABAA, GABAC, Mutagenesis/Chimeric approaches





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics